Somatropin therapy in adults with Prader-Willi syndrome

Treatments in Endocrinology

Volumn 3, Issue 3, 2004, Pages 153-160

  Höybye, Charlotte ^a   Thorén, Marja ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; GROWTH HORMONE; HUMAN GROWTH HORMONE; LIPID; PLACEBO; SOMATOMEDIN C;

BODY COMPOSITION; BODY FAT; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE PREDISPOSITION; EDEMA; FEMALE; GENOTYPE; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HUMAN; HYPOGONADISM; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LEAN BODY WEIGHT; LIPID BLOOD LEVEL; MALE; METABOLIC DISORDER; MUSCLE STRENGTH; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PHENOTYPE; PRADER WILLI SYNDROME; PRIORITY JOURNAL; REVIEW;

ADULT; BODY COMPOSITION; HUMAN GROWTH HORMONE; HUMANS; PRADER-WILLI SYNDROME;

EID: 2642530943     PISSN: 11756349     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024677-200403030-00003     Document Type: Review

References (41)

1. Prader A, Labhart A, Willi H. Ein syndrom von adipositas kleinwuchs, kryptorchismus und oligophrenie nach myatonieartigen zustand im neugeborenalter. Schweiz Med Wochenschr 1956; 86: 1260-1
2. Bray GA, Dahms WT, Swerdloff RS, et al. The Prader-Willi syndrome: a study of 40 patients and a review of the literature. Medicine 1983; 62: 59-80
3. Burd L, Vesely B, Martsolf J, et al. Prevalence study of Prader-Willi syndrome in North Dakota. Am J Med Genet 1990; 37: 97-9
4. Ehara H, Ohno K, Takeshita K. Frequency of the Prader-Willi syndrome in the San-in district, Japan. Brain Dev 1995; 17: 324-6
5. Smith A, Egan J, Ridley E, et al. Birth prevalence of PWS in Australia. Arch Dis Child 2003; 88: 263-4
6. Burman P, Ritzén EM, Lindgren AC. Endocrine dysfunction in Prader-Willi syndrome: a review with special reference to GH. Endocr Rev 2001; 22: 787-99
7. Cassidy S. Prader-Willi syndrome. J Med Genet 1997; 34: 917-23
8. Holm VA, Cassidy SB, Butler MG, et al. Prader-Willi syndrome: consensus diagnostic criteria. Pediatrics 1993; 91: 398-401
9. Butler MG. Prader-Willi syndrome: current understanding of cause and diagnosis. Am J Med Genet 1990; 35: 319-32
10. Dimitropoulos A, Feurer ID, Roof E, et al. Appetite behaviour, compulsivity, and neurochemistry in Prader-Willi syndrome. Ment Retard Dev Disabil Res Rev 2000; 6: 125-30
11. Dykens EM, Leckman JF, Cassidy SB. Obsessions and compulsions in Prader-Willi syndrome. J Child Psychol Psychiatry 1996; 37 (8): 995-1002
12. Cassidy SB. Aging in PWS: 22 patients over age 30 years. Proc Greenwood Genet Center 1994; 13: 102-3
13. Lamb AS, Johnson WM. Premature coronary artery athesclorosis in a patient with Prader-Willi syndrome. Am J Med Genet 1987; 28: 873-80
14. Ledbetter DH, Riccardi VM, Airhart SD, et al. Deletions of chromosome 15 as a cause of the Prader-Willi syndrome. N Engl J Med 1981; 304: 325-9
15. Nicholls RD, Knoll JHM, Butler MG, et al. Genetic imprinting suggested by maternal heterodisomy in non-deletion Prader-Willi syndrome. Nature 1989; 342: 281-5
16. Fridman C, Varela MC, Kok F, et al. Prader-Willi syndrome: genetic tests and clinical findings. Genet Test 2000; 4: 387-92
17. Nicholls RD, Knepper J. Genome organization, function, and imprinting in Prader-Willi and Angelman syndromes. Annu Rev Genomics Hum Genet 2001; 2: 153-75
18. Swaab F, Purba JS, Hofman MA. Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons in Prader-Willi syndrome: a study of five cases. J Clin Endocrinol Metab 1995; 80: 573-9
19. Goldstone A, Unmehopa U, Bloom S, et al. Hypothalamic NPY and agouti-related protein are increased in human illness but not in Prader-Willi syndrome and other obese subjects. J Clin Endocrinol Metab 2002; 87: 927-37
20. Höybye C, Frystyk J, Thorén M. The growth hormone and insulin-like factor axis in adult patients with Prader-Willi syndrome. Growth Horm IGF Res. In press
21. Caroll PV, Christ ER, and the members of Growth Hormone Research Society Scientific Committee. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. J Clin Endocrinol Metab 1998; 83: 382-95
22. Jeffcoate W. Growth hormone therapy and its relationship to insulin resistance, glucose intolerance and diabetes mellitus: a review of recent evidence. Drug Saf 2002; 25: 199-212
23. Eiholzer U, Stutz K, Weinmann C, et al. Low insulin, IGF-I and IGFBP-3 levels in children with Prader-Labhart-Willi syndrome. Eur J Pediatr 1998; 157: 890-3
24. Scuster DP, Osei K, Zipf WB. Characterisation of alterations in glucose and insulin metabolism in Prader-Willi subjects. Metabolism 1996; 45: 1514-20
25. Zipf WB. Glucose homeostasis in Prader-Willi syndrome and potential implications of growth hormone therapy. Acta Paediatr Suppl 1999; 443: 115-7
26. Lindgren AC, Hagenäs L, Ritzén EM. Growth hormone treatment of children with Prader-Willi syndrome: effects on glucose and insulin homeostasis. Swedish National Growth Hormone Advisory Group. Horm Res 1995; 1: 157-61
27. Goldstone AP, Thomas EL, Brynes AE, et al. Visceral adipose tissue and metabolic complications of obesity are reduced in Prader-Willi syndrome female adults: evidence for novel influences on body fat distribution. J Clin Endocrinol Metab 2001; 86: 4330-8
28. Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab 1998; 83: 379-95
29. Bulow B, Hagmar L, Mikoczy Z, et al. Increased cardiovascular mortality in patients with hypopituitarism. Clin Endocrinol 1997; 46: 75-81
30. Rosén T, Eden S, Larsson G, et al. Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh) 1993; 129: 195-200
31. Carel AL, Myers SE, Whitman BY, et al. Growth hormone improves body composition, fat utilisation, physical strength and agility and growth in Prader-Willi syndrome: a controlled study. J Pediatr 1999; 134: 215-21
32. 2 response, ventilation and central respiratory drive in children with Prader-Willi syndrome. Eur J Pediatr 1999; 158: 65-8
33. Höybye C, Hilding A, Jacobsson H, et al. Growth hormone treatment improves body composition in adults with Prader-Willi syndrome. Clin Endocrinol 2003; 58: 653-61
34. Höybye C, Hilding A, Jacobsson H, et al. Metabolic profile and body composition in adults with Prader-Willi syndrome and severe obesity. J Clin Endocrinol Metab 2002; 87: 3590-7
35. Jorgensen JOL, Pedersen SA, Thuesen L, et al. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1989; I: 1221-4
36. Bengtsson BA, Abs R, Bennmarker H, et al. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults: KIMS Study Group and the KIMS International Board. J Clin Endocrinol Metab 1999; 84 (11): 3295-35
37. Johannsson G, Rosén T, Bengtsson BA. Individualized dose titration of growth hormone (GH) replacement in hypopituitary adults. Clin Endocrinol (Oxf) 1997; 47: 571-81
38. Bosio L, Beccaria L, Benzi F, et al. Body composition during GH treatment in Prader-Willi syndrome. J Pediatr Endocrinol Metab 1999; 12: 351-3
39. Carrel AL, Myers SE, Whitman BY, et al. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4 year study. J Clin Endocrinol Metab 2002; 87: 1581-5
40. Greenswag LR. Adults with Prader-Willi syndrome: a survey of 232 cases. Dev Med Child Neurol 1987; 29: 145-52
41. l'Allemand D, Eiholzer U, Schlumpf M, et al. Cardiovascular risk factors improve under 3 years of growth hormone therapy in Prader-Willi syndrome. Eur J Pediatr 2000; 159: 835-42